A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals

Sandra Andorf, Natasha Purington, Divya Kumar, Andrew Long, Katherine L. O'Laughlin, Scott Sicherer, Hugh Sampson, Antonella Cianferoni, Terri Brown Whitehorn, Daniel Petroni, Melanie Mala Makhija, Rachel G Robison, Michelle Lierl, Stephanie Logsdon, Manisha Desai, Stephen J. Galli, Efren Rael, Amal Assa'ad, Sharon Chinthrajah, Jacqueline A PongracicJonathan M. Spergel, Jonathan Tam, Stephen Tilles, Julie Wang, Kari Nadeau*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Background: As there is limited data on the sustainability of desensitization of multifood-oral immunotherapy (multifood-OIT), we conducted a multisite multifood-OIT study to compare the efficacy of successful desensitization with sustained dosing vs discontinued dosing after multifood-OIT. Methods: We enrolled 70 participants, aged 5–22 years with multiple food allergies confirmed by double-blind placebo-controlled food challenges (DBPCFCs). In the open-label phase of the study, all participants received omalizumab (weeks 1–16) and multi-OIT (2–5 allergens; weeks 8–30) and eligible participants (on maintenance dose of each allergen by weeks 28–29) were randomized 1:1:1 to 1 g, 300 mg, or 0 mg arms (blinded, weeks 30–36) and then tested by food challenge at week 36. Success was defined as passing 2 g food challenge to at least 2 foods in week 36. Findings: Most participants were able to reach a dose of 2 g or higher of each of 2, 3, 4, and 5 food allergens (as applicable to the participant's food allergens in OIT) in week 36 food challenges. Using an intent-to-treat analysis, we did not find evidence that a 300 mg dose was effectively different than a 1 g dose in maintaining desensitization, and both together were more effective than OIT discontinuation (0 mg dose) (85% vs 55%, P = 0.03). Fifty-five percent of the intent-to-treat participants and 69% of per protocol participants randomized to the 0 mg arm showed no objective reactivity after 6 weeks of discontinuation. Cross-desensitization was found between cashew/pistachio and walnut/pecan when only one of the foods was part of OIT. No statistically significant safety differences were found between the three arms. Interpretation: These results suggest that sustained desensitization after omalizumab-facilitated multi-OIT best occurs through continued maintenance OIT dosing of either 300 mg or 1 g of each food allergen as opposed to discontinuation of multi-OIT. Funding: Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Jeff and MacKenzie Bezos, NIAID AADCRC U19AI104209. Trial Registration Number: ClinicalTrials.gov number, NCT02626611.

Original languageEnglish (US)
Pages (from-to)27-38
Number of pages12
StatePublished - Jan 2019


  • Food allergen
  • Food allergy
  • Omalizumab
  • Oral immunotherapy
  • Sustained unresponsiveness

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals'. Together they form a unique fingerprint.

Cite this